Allspring中小型核心主动型ETF ASCE 深 沪
等待开盘 03-26 09:30:00 美东时间
28.1238
+0.304
+1.09%
华盛通- 最 高28.20
- 今 开27.95
- 成交量 4.97万股
- 最 低 27.95
- 昨 收 27.82
- 总市值 5020.11万
- 52周最高 32.41
- 市盈率 静 --
- 换手率 2.78%
- 52周最低 24.0619
- 委 比 0.00%
- 总股本 178.50万
- 历史最高 32.41
- 量 比 2.35
- 振 幅 0.90%
- 历史最低 24.0619
- 每 手 1
- 风险率 1.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ADMA Biologics drops amid short report from Culper Research
ADMA Biologics (ADMA) fell 15% amid a short report from Culper Research. Culper Research disclosed that it's short shares of ADMA Biologics (ADMA). ADMA (ADMA) didn't immediately respond to Seeking ...
03-25 02:44
Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with
03-18 20:33
Hepion Pharmaceuticals FY 2025 net loss widens 37% to USD 8.28 million as R&D expense falls 96% to USD 0.45 million
Hepion Pharmaceuticals FY 2025 net loss widens 37% to USD 8.28 million as R&D expense falls 96% to USD 0.45 million Hepion reported no revenue for FY 2025 and posted a net loss of USD 8.28 million, narrowing 37% year over year. Loss from operations was USD 4.16 million, narrowing 78%, as research an
03-12 18:07
Amarin Published Data In The European Journal Of Preventive Cardiology Showing That VASCEPA Was Associated With Fewer Hospitalizations In A REDUCE-IT Analysis
Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on
03-02 21:16
ADMA Biologics announces $125M accelerated share repurchase with JPmorgan
ADMA Biologics (ADMA) announced on Monday a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”) a...
03-02 20:46
BRIEF-Zealand Pharma Announces Positive Phase 1A Topline Results With Kv1.3 Channel Blocker Zp9830
BRIEF-Zealand Pharma Announces Positive Phase 1A Topline Results With Kv1.3 Channel Blocker Zp9830 Feb 18 (Reuters) - Zealand Pharma A/S ZELA.CO : ANNOUNCES POSITIVE PHASE 1A TOPLINE RESULTS WITH KV1.3 CHANNEL BLOCKER ZP9830 ZP9830 WAS WELL TOLERATED IN THIS SINGLE ASCENDING DOSE TRIAL, WITH NO DOSE
02-18 14:36
BRIEF-Ascender Capital Calls For Improved Capital Allocation And Governance At Argo Graphics
BRIEF-Ascender Capital Calls For Improved Capital Allocation And Governance At Argo Graphics Feb 11 (Reuters) - Argo Graphics Inc 7595.T : ASCENDER CAPITAL CALLS FOR IMPROVED CAPITAL ALLOCATION AND GOVERNANCE AT ARGO GRAPHICS (7595) ASCENDER CAPITAL: REQUESTS ARGO FOR ADDITIONAL ¥125 PER‑SHARE SPECI
02-11 23:41
BRIEF-Ascend Wellness Holdings Inc Outlook Q4 2025 Revenue Of $120 Million, FY 2025 $500 Million
BRIEF-Ascend Wellness Holdings Inc Outlook Q4 2025 Revenue Of $120 Million, FY 2025 $500 Million Feb 9 (Reuters) - Ascend Wellness Holdings Inc AAWH.PK : ASCEND WELLNESS HOLDINGS INC - OUTLOOK Q4 2025 REVENUE OF $120 MILLION, FY 2025 $500 MILLION ASCEND WELLNESS HOLDINGS INC - OUTLOOK Q4 2025 EBITDA
02-09 22:55
Liquidia Unveils New Clinical Data on Inhaled Treprostinil Therapies at PVRI 2026 Congress
Liquidia Unveils New Clinical Data on Inhaled Treprostinil Therapies at PVRI 2026 Congress Liquidia Corporation announced that it will present new clinical data across its portfolio at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress, taking place January 28 through February 1,
01-28 01:27
